1. Home
  2. CYTK vs BEPC Comparison

CYTK vs BEPC Comparison

Compare CYTK & BEPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$68.45

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Logo Brookfield Renewable Corporation

BEPC

Brookfield Renewable Corporation

HOLD

Current Price

$41.44

Market Cap

7.4B

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
BEPC
Founded
1997
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Electric Utilities: Central
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
7.4B
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
CYTK
BEPC
Price
$68.45
$41.44
Analyst Decision
Strong Buy
Buy
Analyst Count
15
4
Target Price
$77.87
$39.75
AVG Volume (30 Days)
1.9M
1.4M
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
3.60%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$87,211,000.00
$3,828,000,000.00
Revenue This Year
$363.61
$43.05
Revenue Next Year
$64.33
$9.08
P/E Ratio
N/A
N/A
Revenue Growth
2609.26
N/A
52 Week Low
$29.31
$23.73
52 Week High
$69.33
$45.10

Technical Indicators

Market Signals
Indicator
CYTK
BEPC
Relative Strength Index (RSI) 62.93 50.01
Support Level $59.85 $40.17
Resistance Level $67.98 $41.96
Average True Range (ATR) 2.72 1.17
MACD 0.13 -0.38
Stochastic Oscillator 91.35 25.15

Price Performance

Historical Comparison
CYTK
BEPC

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About BEPC Brookfield Renewable Corporation

Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia, and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners LP and Brookfield Renewable Corp.

Share on Social Networks: